Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) is a leading force in the biopharmaceutical industry, dedicated to developing innovative targeted radiotherapies that offer hope to patients who have not responded to existing oncology treatments. As a publicly traded, late-stage biopharmaceutical company, Actinium's mission is to meaningfully improve survival rates for these patients through advanced therapeutic solutions. Analysts who cover ATNM have an average price target over 300% higher than current levels. This is clearly a stock that has the attention of the market right now.
Iomab-B: A Breakthrough in Bone Marrow Transplant Preparation
Actinium’s flagship product, Iomab-B, is a pioneering therapy licensed from the esteemed Fred Hutchinson Cancer Research Center. Iomab-B is designed to prepare patients for hematopoietic stem cell transplants (HSCT), commonly known as bone marrow transplants. This procedure is often the only potential cure for patients with blood-borne cancers. However, the current standard preparation involves high-dose chemotherapy and/or total body irradiation, which come with significant toxicities.
Iomab-B has shown promising results in the pivotal Phase 3 SIERRA trial, indicating that it can provide a faster, less toxic alternative for transplant preparation. By targeting cancerous cells and sparing healthy tissues, Iomab-B is expected to increase transplant success rates and improve overall survival outcomes for patients.
Actimab-A: Advancing the Frontier of AML Treatment
Another groundbreaking therapy in Actinium's pipeline is Actimab-A, the company's lead alpha particle drug candidate. Actimab-A is under development in collaboration with the National Cancer Institute (NCI) through a Cooperative Research and Development Agreement (CRADA). It is being studied in combination with other treatments for acute myeloid leukemia (AML), leveraging its mutation-agnostic and resistant mechanism of action.
Actimab-A targets CD33, a marker ubiquitously expressed in AML patients, and is conjugated with the potent alpha-particle payload Actinium-225. This targeted approach ensures that the radiotherapy is delivered directly to the cancer cells, minimizing damage to healthy cells. Actimab-A has shown potent in vitro AML cell-killing activity and has demonstrated enhanced effectiveness when combined with menin inhibitors, such as revumenib and ziftomenib, particularly in difficult-to-treat KMT2A mutant AML.
Recent Developments: Synergistic Potential of Actimab-A and Menin Inhibitors
Actinium recently presented groundbreaking preclinical data at the 2024 European Hematology Association (EHA) Congress, highlighting the synergistic effects of combining Actimab-A with menin inhibitors. These inhibitors, including revumenib and ziftomenib, target specific genetic mutations present in a significant subset of AML patients.
Key findings from the studies include:
- Potent AML Cell Killing: Actimab-A as a single agent showed superior AML cell killing activity compared to non-radio conjugated CD33 antibody lintuzumab.
- Enhanced Cell Death: The combination of Actimab-A with menin inhibitors significantly enhanced AML cell death and triggered acute increases in necrosis and cell death in vivo within 72 hours of dosing.
- Prolonged Anti-Tumor Effect: The anti-tumor effect was significantly potentiated and prolonged when Actimab-A was combined with menin inhibitors compared to monotherapies.
The Future of Actimab-A and Menin Inhibitors in AML Treatment
The promising results from combining Actimab-A with menin inhibitors underscore the potential of this approach across various stages of AML treatment, including frontline, maintenance, and relapsed/refractory settings. Sandesh Seth, Actinium's Chairman and CEO, expressed enthusiasm about the initial data, highlighting the broad potential of Actimab-A as a backbone therapy in AML treatment due to its potency and mutation-agnostic nature.
Actinium Pharmaceuticals is poised to revolutionize the treatment landscape for blood cancers and solid tumors through its innovative targeted radiotherapies. With promising products like Iomab-B and Actimab-A, the company is making significant strides toward improving patient outcomes and offering new hope to those who have exhausted existing treatment options. As Actinium continues to advance its drug development pipeline and explore synergistic treatment combinations, the future looks bright for patients and the field of oncology.
For more detailed information and updates on Actinium Pharmaceuticals' groundbreaking work https://www.actiniumpharma.com.
Besides ATNM, other notable stocks to keep on top of radar include NuZee, Inc. (NASDAQ: NUZE), Dermata Therapeutics, Inc. (NASDAQ: DRMA), Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Bone Biologics Corporation (NASDAQ: BBLG)
Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://digitalcoinstandard.com//disclaimer/. https://digitalcoinstandard.com/ has been compensated five hundred dollars by a 3rd party Momentum Media LLC for content distribution services on ATNM for July 25th, 2024. https://digitalcoinstandard.com/ is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of https://digitalcoinstandard.com/ is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.https://digitalcoinstandard.com/ does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.https://digitalcoinstandard.com/ is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by https://digitalcoinstandard.com/ or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. https://digitalcoinstandard.com/ is not a fiduciary by virtue of any person’s use of or access to this content.
Source:
1. https://ir.actiniumpharma.com/press-releases
Media Contact
Company Name: DigitalCoinStandard
Contact Person: Ash K
Email: editor@digitalcoinstandard.com
Country: United States
Website: https://digitalcoinstandard.com/
